TY  - JOUR
AU  - Džudović, Jelena
AU  - Crevar-Sakač, Milkica
AU  - Antunović, Marko
AU  - Repić, Aleksandra
AU  - Obradović, Slobodan
AU  - Đorđević, Snežana
AU  - Savić, Jelena
AU  - Džudović, Boris
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4332
AB  - Oral anticoagulants are a group of drugs used for the prevention and treatment of venous thrombosis and venous thromboembolism. For the last ten years, direct oral anticoagulants (DOAC) have been available and are equally effective, but significantly safer than vitamin K antagonists. In the case of an overdose, their most important side effect is still bleeding. Due to their widespread use, as well as increased toxicological importance there is a need to develop an analytical method for the determination of DOAC in biological material. The aim of this paper was to establish a method for the quantification of apixaban as one of the representatives of DOAC. The methodology of the study included the measurement of apixaban in the plasma of patients treated in the intensive care unit. Plasma apixaban concentrations were determined by LC-MS/MS technique using carbamazepine as an internal standard. Obtained validation parameters indicate that the introduced method is sensitive, reliable, precise and accurate. Using this method, apixaban can be quickly and easily detected and quantified in plasma in patients who are suspected of overdosing with this drug.
PB  - Akademiai Kiado ZRt.
T2  - Acta Chromatographica
T1  - Development and validation of LC-MS/MS method for determination of plasma apixaban
VL  - 34
IS  - 3
SP  - 332
EP  - 337
DO  - 10.1556/1326.2021.00948
ER  - 

@article{
author = "Džudović, Jelena and Crevar-Sakač, Milkica and Antunović, Marko and Repić, Aleksandra and Obradović, Slobodan and Đorđević, Snežana and Savić, Jelena and Džudović, Boris",
year = "2022",
abstract = "Oral anticoagulants are a group of drugs used for the prevention and treatment of venous thrombosis and venous thromboembolism. For the last ten years, direct oral anticoagulants (DOAC) have been available and are equally effective, but significantly safer than vitamin K antagonists. In the case of an overdose, their most important side effect is still bleeding. Due to their widespread use, as well as increased toxicological importance there is a need to develop an analytical method for the determination of DOAC in biological material. The aim of this paper was to establish a method for the quantification of apixaban as one of the representatives of DOAC. The methodology of the study included the measurement of apixaban in the plasma of patients treated in the intensive care unit. Plasma apixaban concentrations were determined by LC-MS/MS technique using carbamazepine as an internal standard. Obtained validation parameters indicate that the introduced method is sensitive, reliable, precise and accurate. Using this method, apixaban can be quickly and easily detected and quantified in plasma in patients who are suspected of overdosing with this drug.",
publisher = "Akademiai Kiado ZRt.",
journal = "Acta Chromatographica",
title = "Development and validation of LC-MS/MS method for determination of plasma apixaban",
volume = "34",
number = "3",
pages = "332-337",
doi = "10.1556/1326.2021.00948"
}

Džudović, J., Crevar-Sakač, M., Antunović, M., Repić, A., Obradović, S., Đorđević, S., Savić, J.,& Džudović, B.. (2022). Development and validation of LC-MS/MS method for determination of plasma apixaban. in Acta Chromatographica
Akademiai Kiado ZRt.., 34(3), 332-337.
https://doi.org/10.1556/1326.2021.00948

Džudović J, Crevar-Sakač M, Antunović M, Repić A, Obradović S, Đorđević S, Savić J, Džudović B. Development and validation of LC-MS/MS method for determination of plasma apixaban. in Acta Chromatographica. 2022;34(3):332-337.
doi:10.1556/1326.2021.00948 .

Džudović, Jelena, Crevar-Sakač, Milkica, Antunović, Marko, Repić, Aleksandra, Obradović, Slobodan, Đorđević, Snežana, Savić, Jelena, Džudović, Boris, "Development and validation of LC-MS/MS method for determination of plasma apixaban" in Acta Chromatographica, 34, no. 3 (2022):332-337,
https://doi.org/10.1556/1326.2021.00948 . .

TY  - JOUR
AU  - Ivković, Branka
AU  - Opačić, Dragan
AU  - Džudović, Boris
AU  - Crevar, Milkica
AU  - Gojković-Bukarica, Ljiljana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4306
AB  - It is well known that the presence of different chemical groups in drug molecules influences their pharmacological properties. The aim of our study is to investigate whether newly synthesized derivatives of propafenone, with changes in benzyl moiety, have a different effect upon arrhythmia, compared to propafenone. 5OCl-PF and 5OF-PF are derivatives of propafenone with-Cl or –F substituent on the ortho position of the benzyl moiety. For verification of their antiarrhythmic effect, we used an in vivo rat model of aconitine-induced arrhythmia. 5OCl-PF speeded the appearance of supraventricular premature beats (SVPB) and death more than aconitine. All animals treated with 5OCl-PF developed ventricular premature beats in salvos (VPBS), bigeminies (VPBB) and paroxysmal ventricular tachycardia (PVT). 5OF-PF had a negative chronotropic effect and potentiated atrial excitability (more SVPB). It had a positive effect on the occurrence and onset time of supraventricular tachycardia, VPBS, and PVT. Based on the obtained results, it can be concluded that newly synthesized propafenone derivatives have no better antiarrhythmic effect than the parent compound. In the future, our research will be focused on the synthesis of different derivatives and examining their antiarrhythmic effects.
AB  - Dobro je poznato da prisustvo različitih hemijskih grupa u molekulima leka utiče na
njegova farmakološka svojstva. Cilj našeg istraživanja je ispitati da li novosintetisani derivati
propafenona, s promenama u benzilnoj grupi, imaju drugačiji efekat na aritmiju u odnosu na
propafenon. 5OCl-PF i 5OF-PF su derivati propafenona sa -Cl ili –F supstituentom na orto
položaju benzilnog dela. Za proveru njihovog antiaritmičnog efekta koristili smo in vivo model
na pacovima sa aritmijom izazvanom akonitinom. 5OCl-PF je ubrzao pojavu
supraventrikularnih prevremenih otkucaja (SVPB) i smrt više nego akonitin. Sve životinje
lečene sa 5OCl-PF razvile su ventrikularne prevremene otkucaje (VPBS i VPBB) i
paroksizmalnu ventrikularnu tahikardiju (PVT). 5OF-PF je imao negativan hronotropni efekat i
potencirao atrijalnu ekscitabilnost (više SVPB). Pozitivno je uticao na pojavu i vreme početka
supraventrikularne tahikardije, VPBS i PVT. Na osnovu dobijenih rezultata se može zaključiti
da novosintetisani derivati propafenona nemaju bolji antiaritmijski efekat od polaznog
jedinjenja. U budućnosti, istraživanje će biti usmereno ka sintezi hemijski drugačijih derivata i
ispitivanju njihovog antiaritmijskog efekta.
PB  - Pharmaceutical Association of Serbia
T2  - Arhiv za farmaciju
T1  - Antiarrhythmic effects of newly developed propafenone derivatives
T1  - Antiaritmički efekti novosintetisanih derivata
propafenona
VL  - 72
IS  - 4
SP  - 392
EP  - 412
DO  - 10.5937/arhfarm72-37114
ER  - 

@article{
author = "Ivković, Branka and Opačić, Dragan and Džudović, Boris and Crevar, Milkica and Gojković-Bukarica, Ljiljana",
year = "2022",
abstract = "It is well known that the presence of different chemical groups in drug molecules influences their pharmacological properties. The aim of our study is to investigate whether newly synthesized derivatives of propafenone, with changes in benzyl moiety, have a different effect upon arrhythmia, compared to propafenone. 5OCl-PF and 5OF-PF are derivatives of propafenone with-Cl or –F substituent on the ortho position of the benzyl moiety. For verification of their antiarrhythmic effect, we used an in vivo rat model of aconitine-induced arrhythmia. 5OCl-PF speeded the appearance of supraventricular premature beats (SVPB) and death more than aconitine. All animals treated with 5OCl-PF developed ventricular premature beats in salvos (VPBS), bigeminies (VPBB) and paroxysmal ventricular tachycardia (PVT). 5OF-PF had a negative chronotropic effect and potentiated atrial excitability (more SVPB). It had a positive effect on the occurrence and onset time of supraventricular tachycardia, VPBS, and PVT. Based on the obtained results, it can be concluded that newly synthesized propafenone derivatives have no better antiarrhythmic effect than the parent compound. In the future, our research will be focused on the synthesis of different derivatives and examining their antiarrhythmic effects., Dobro je poznato da prisustvo različitih hemijskih grupa u molekulima leka utiče na
njegova farmakološka svojstva. Cilj našeg istraživanja je ispitati da li novosintetisani derivati
propafenona, s promenama u benzilnoj grupi, imaju drugačiji efekat na aritmiju u odnosu na
propafenon. 5OCl-PF i 5OF-PF su derivati propafenona sa -Cl ili –F supstituentom na orto
položaju benzilnog dela. Za proveru njihovog antiaritmičnog efekta koristili smo in vivo model
na pacovima sa aritmijom izazvanom akonitinom. 5OCl-PF je ubrzao pojavu
supraventrikularnih prevremenih otkucaja (SVPB) i smrt više nego akonitin. Sve životinje
lečene sa 5OCl-PF razvile su ventrikularne prevremene otkucaje (VPBS i VPBB) i
paroksizmalnu ventrikularnu tahikardiju (PVT). 5OF-PF je imao negativan hronotropni efekat i
potencirao atrijalnu ekscitabilnost (više SVPB). Pozitivno je uticao na pojavu i vreme početka
supraventrikularne tahikardije, VPBS i PVT. Na osnovu dobijenih rezultata se može zaključiti
da novosintetisani derivati propafenona nemaju bolji antiaritmijski efekat od polaznog
jedinjenja. U budućnosti, istraživanje će biti usmereno ka sintezi hemijski drugačijih derivata i
ispitivanju njihovog antiaritmijskog efekta.",
publisher = "Pharmaceutical Association of Serbia",
journal = "Arhiv za farmaciju",
title = "Antiarrhythmic effects of newly developed propafenone derivatives, Antiaritmički efekti novosintetisanih derivata
propafenona",
volume = "72",
number = "4",
pages = "392-412",
doi = "10.5937/arhfarm72-37114"
}

Ivković, B., Opačić, D., Džudović, B., Crevar, M.,& Gojković-Bukarica, L.. (2022). Antiarrhythmic effects of newly developed propafenone derivatives. in Arhiv za farmaciju
Pharmaceutical Association of Serbia., 72(4), 392-412.
https://doi.org/10.5937/arhfarm72-37114

Ivković B, Opačić D, Džudović B, Crevar M, Gojković-Bukarica L. Antiarrhythmic effects of newly developed propafenone derivatives. in Arhiv za farmaciju. 2022;72(4):392-412.
doi:10.5937/arhfarm72-37114 .

Ivković, Branka, Opačić, Dragan, Džudović, Boris, Crevar, Milkica, Gojković-Bukarica, Ljiljana, "Antiarrhythmic effects of newly developed propafenone derivatives" in Arhiv za farmaciju, 72, no. 4 (2022):392-412,
https://doi.org/10.5937/arhfarm72-37114 . .